CareDx Options Unwind Ahead of Q3 Print

CDNA gained 2.1% on Tuesday and is up 10.8% over the past month, trading at $70.53 ahead of Thursday's Q3 results. Among its closest US diagnostics peers, NTRA rose 1.5% on the day and 1.2% on the week, while TWST jumped 10.1% on Tuesday and 12% on the week. CDNA's 1.9% weekly gain trails that peer median of roughly 2.3%, modest underperformance for a stock that has run nearly 200% year-to-date.

The most striking shift in the positioning data is a rapid unwind of the defensive options posture that defined September. The put/call ratio has dropped to 1.44, almost three standard deviations below its 20-day average of 1.92, a level that had climbed as high as 4.88 over the past year. Through most of October and all of late September, traders were heavily skewed toward puts. That skew has collapsed in the days immediately ahead of the print, meaning the options market is far less defensively positioned now than it was a month ago. Short interest, meanwhile, has fallen 8.1% over the past week to 12.9% of the free float, a meaningful level but moving in the wrong direction for bears. Borrow conditions remain relaxed: availability is running at roughly 2,276% of short interest, well above even the 52-week floor of 649%, and the cost to borrow is just 0.42%. There is no mechanical pressure on short sellers heading into the release.

Analysts have been steadily ratcheting targets higher. Canaccord raised its target from $65 to $80 on October 19, maintaining a Buy, after BTIG moved its own Buy-rated target from $60 to $74 in late September. Both lifts came in response to Q2 revenue of $132 million, up 52% year-on-year, and management's raised 2026 revenue guide of $490 million to $500 million. The consensus mean price target of $65.33 now sits below the current share price, a typical feature of a stock that has moved faster than published targets. HC Wainwright holds a Neutral at $46, a dissenting note in an otherwise constructive analyst picture. The bull case rests on the removal of the transplant LCD reimbursement overhang and the potential second growth engine from the planned AlloHeme launch. The bear case centres on concentration in AlloSure Kidney and AlloMap Heart, plus integration risk from the Naveris acquisition.

One ownership detail is worth noting. BlackRock increased its position to 9.0% of the class in its most recent 13G/A filing in July, up from 8.0% previously, making it the largest disclosed holder. ARK Investment Management, a name associated with higher-conviction growth bets, holds 3.8% of shares as of September 30. Baron Capital trimmed its position by 236,320 shares in the same period. Insider activity has been dominated by tax-withholding transactions coded as share disposals, including a $564,000 withholding from the CEO on October 1. These are compensation mechanics rather than discretionary sales, and no open-market purchases appear in the recent record.

The Q3 print will test whether the 52% revenue growth rate from Q2 is being maintained or whether volume and pricing momentum have moderated in a quarter that matters for full-year guidance credibility.